ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

On Biomedical Malthusianism; Varmus, et al. Propose a Strategy For Saving Biomedical Research

May 2, 2014

DeVita Appointment Now Official; Calls For New Chemoprevention Program, More Applied Prevention

July 18, 1980

Lung Cancer Mortality Begins to decline Among Under 55 Group

April 6, 1990

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

Over $20 Million Carved Out From Statistical, Operations Centers

May 16, 2014